Announcements

New Impact Factor of CJCR: 0.932!

Published: 2014-07-30

Great News! The Impact Factor of Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) has more than doubled from 0.448 to 0.932 this year.

In the recent two years, the journal has been making progresses in a steady way. Its IF has grown from 0.182 (2011), to 0.448 (2012) and now to 0.932 (2013). The journal developed from a quarterly publication to a bi-monthly journal in 2013. In 2012, we published 64 papers, yet the number increased to 124 in 2013.

In the past one year, CJCR has also made its debut in many international meetings, such as WCLC, ASTRO, AACR (fig.1) and ASCO (fig.2), for exhibitions as a way to further communicate with our readers and authors.















Figure 1: CJCR exhibited in the 105th American Association for Cancer Research (AACR) annual meeting during April 6th to 9th,2014 in San Diego, USA











Figure 2: Executive Editor-in-Chief of CJCR, Prof. Jiafu Ji visited our exhibition booth in the 50th American Society for Clinical Oncology (ASCO) annual meeting held during May 30 to June 3, 2014 in Chicago,Illinois, USA.

On behalf of our Honorary Editor-in-Chief, Yan Sun, Editor-in-Chief, Yang Ke and Executive Editor-in-Chief, Jiafu Ji, we would like to take this chance to express our heartfelt thanks to our outstanding editorial board members, reviewers, authors and readers for their support and fine contributions. In the future, with the join efforts and continued support from the editorial board members, reviewers, authors and readers worldwide, we are determined to bring our journal to a novel level in this academic arena of cancer research and make it a robust platform for more doctors and investigators worldwide.

CJCR is ABSTRACTED/INDEXED IN:
Science Citation Index Expanded (SciSearch), PubMed Central, PubMed, Scoups, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, CSA, Academic One File, Chinese Science Citation Database, Gale, Journal Citation Reports/Science Edition, OCLC, SCImago, Summon by Serial Solutions.